Linked e-resources
Details
Table of Contents
Intro; Abstract; Kurzfassung; Abrégé; Preface; Acknowledgements; Overview; Content Outline; List of Abbreviations; List of Tables; List of Figures; 1 Research concept; 1 Problem; 2 Research goal; 3 Research question; 4 Methodology; 4.1 Theoretical part; 4.2 Applied part; 4.3 Derivation and evaluation of policy levers; 5 Research gap; 5.1 Degree of novelty of research question; 5.2 Application of established methodology in new context; 6 Epistemological foundations; 6.1 Law and Economics; 6.2 New Institutional Economics; 6.2.1 Definition of institutions
6.2.2 Overlap of New Institutional Economics with Law and Economics6.2.3 Underlying assumption: Institutions influence innovation; 6.3 Translational Medicine; 7 Underlying assumption; 8 Scope; 8.1 In scope: Non-science related institutional barriers to the translation of personalized medicine into clinical practice; 8.2 In scope: Geographic focus on Switzerland in applied part; 8.3 Out of scope: Direct-to-consumer tests (DTCs); 8.4 Out of scope: Prenatal tests; 8.5 Out of scope: Ethical challenges in the context of personalized medicine; 9 Structure
2 Part I: Definitions & terminologies. Overview of terminologies used in the context of personalized medicine1 Definition of personalized medicine; 1.1 Different understandings of personalized medicine; 1.1.1 Synonyms for personalized medicine; 1.1.2 Closely related terms; 1.2 PM's underlying mechanism; 1.3 Working definition of personalized medicine; 2 Terminologies used for personalized medicine diagnostics; 2.1 Personalized medicine diagnostics; 2.2 Companion diagnostics; 2.3 Categories of personalized medicine diagnostics; 2.3.1 Diagnostic tests for somatic vs germline variations
2.3.2 Presymptomatic vs diagnostic tests3 Other terminologies used in the context of personalized medicine; 3.1 Biomarker; 3.1.1 Categories; 3.1.2 Single Nucleotide Polymorphisms; 3.1.3 „Omics"-based biomarkers; 3.2 Biobanks; 3.3 Next generation sequencing; 3 Part II: Context. Description of personalized medicine's impact on the healthcare landscape; 1 Personalized medicine
a paradigm shift in healthcare; 1.1 Historical background; 1.2 Status quo; 1.2.1 Number of personalized medicine applications; 1.2.2 National and international personalized medicine initiatives; 1.3 Future developments
1.3.1 Tapping new scientific potential1.3.2 New nosology through personalized medicine; 1.3.3 Increased use of multi-target personalized medicine diagnostics; 1.3.4 Shift from reaction to prevention; 1.3.5 Impact on hospitals' organization; 1.3.6 Increase in patient involvement; 1.3.7 Prospect of human gene editing; 2 Goals of personalized medicine; 2.1 Risk assessment & prevention; 2.2 Accurate diagnosis; 2.3 Elimination of unnecessary treatments; 2.4 Reduction of adverse drug reactions; 2.5 Improved dosing; 2.6 Improved monitoring; 2.7 Targeted development
6.2.2 Overlap of New Institutional Economics with Law and Economics6.2.3 Underlying assumption: Institutions influence innovation; 6.3 Translational Medicine; 7 Underlying assumption; 8 Scope; 8.1 In scope: Non-science related institutional barriers to the translation of personalized medicine into clinical practice; 8.2 In scope: Geographic focus on Switzerland in applied part; 8.3 Out of scope: Direct-to-consumer tests (DTCs); 8.4 Out of scope: Prenatal tests; 8.5 Out of scope: Ethical challenges in the context of personalized medicine; 9 Structure
2 Part I: Definitions & terminologies. Overview of terminologies used in the context of personalized medicine1 Definition of personalized medicine; 1.1 Different understandings of personalized medicine; 1.1.1 Synonyms for personalized medicine; 1.1.2 Closely related terms; 1.2 PM's underlying mechanism; 1.3 Working definition of personalized medicine; 2 Terminologies used for personalized medicine diagnostics; 2.1 Personalized medicine diagnostics; 2.2 Companion diagnostics; 2.3 Categories of personalized medicine diagnostics; 2.3.1 Diagnostic tests for somatic vs germline variations
2.3.2 Presymptomatic vs diagnostic tests3 Other terminologies used in the context of personalized medicine; 3.1 Biomarker; 3.1.1 Categories; 3.1.2 Single Nucleotide Polymorphisms; 3.1.3 „Omics"-based biomarkers; 3.2 Biobanks; 3.3 Next generation sequencing; 3 Part II: Context. Description of personalized medicine's impact on the healthcare landscape; 1 Personalized medicine
a paradigm shift in healthcare; 1.1 Historical background; 1.2 Status quo; 1.2.1 Number of personalized medicine applications; 1.2.2 National and international personalized medicine initiatives; 1.3 Future developments
1.3.1 Tapping new scientific potential1.3.2 New nosology through personalized medicine; 1.3.3 Increased use of multi-target personalized medicine diagnostics; 1.3.4 Shift from reaction to prevention; 1.3.5 Impact on hospitals' organization; 1.3.6 Increase in patient involvement; 1.3.7 Prospect of human gene editing; 2 Goals of personalized medicine; 2.1 Risk assessment & prevention; 2.2 Accurate diagnosis; 2.3 Elimination of unnecessary treatments; 2.4 Reduction of adverse drug reactions; 2.5 Improved dosing; 2.6 Improved monitoring; 2.7 Targeted development